Dianthus Therapeutics (NASDAQ:DNTH) CFO Sells 20,000 Shares

Key Points

• Dianthus Therapeutics CFO Ryan Savitz sold 20,000 shares for a total of $700,000 at an average price of $35.00 on September 9th.
• The company reported a loss of ($0.88) earnings per share for the last quarter, missing estimates, and had revenue of only $0.19 million.
• Several analysts have issued upward revisions to their price targets for DNTH, with Guggenheim raising its target from $92.00 to $100.00, reflecting a positive outlook on the stock.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CFO Ryan Savitz sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Dianthus Therapeutics Price Performance

Shares of DNTH traded down $0.03 during midday trading on Thursday, reaching $37.87. 1,172,091 shares of the stock were exchanged, compared to its average volume of 388,952. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $38.59. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -11.65 and a beta of 1.46. The business's 50-day moving average price is $22.28 and its 200 day moving average price is $20.32.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNTH. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. RA Capital Management L.P. boosted its stake in Dianthus Therapeutics by 53.6% during the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after buying an additional 1,000,333 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Dianthus Therapeutics in the 1st quarter worth approximately $4,510,000. Octagon Capital Advisors LP increased its holdings in shares of Dianthus Therapeutics by 11.0% in the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after buying an additional 231,500 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DNTH shares. William Blair started coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Wedbush boosted their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Raymond James Financial reaffirmed an "outperform" rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday. Guggenheim raised their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Robert W. Baird upped their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Dianthus Therapeutics currently has an average rating of "Buy" and an average target price of $60.67.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.